Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

A chemically programmed antibody is a long-lasting and potent inhibitor of influenza neuraminidase.

Hayakawa M, Toda N, Carrillo N, Thornburg NJ, Crowe JE Jr, Barbas CF 3rd.

Chembiochem. 2012 Oct 15;13(15):2191-5. doi: 10.1002/cbic.201200439. Epub 2012 Sep 10.

2.

From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs?

Cheng CK, Tsai CH, Shie JJ, Fang JM.

Future Med Chem. 2014 May;6(7):757-74. doi: 10.4155/fmc.14.30. Review.

PMID:
24941871
3.

Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.

Watson KG, Cameron R, Fenton RJ, Gower D, Hamilton S, Jin B, Krippner GY, Luttick A, McConnell D, MacDonald SJ, Mason AM, Nguyen V, Tucker SP, Wu WY.

Bioorg Med Chem Lett. 2004 Mar 22;14(6):1589-92.

PMID:
15006410
4.

Recent advances in neuraminidase inhibitor development as anti-influenza drugs.

Feng E, Ye D, Li J, Zhang D, Wang J, Zhao F, Hilgenfeld R, Zheng M, Jiang H, Liu H.

ChemMedChem. 2012 Sep;7(9):1527-36. doi: 10.1002/cmdc.201200155. Epub 2012 Jul 16. Review.

PMID:
22807317
5.

Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza.

Macdonald SJ, Cameron R, Demaine DA, Fenton RJ, Foster G, Gower D, Hamblin JN, Hamilton S, Hart GJ, Hill AP, Inglis GG, Jin B, Jones HT, McConnell DB, McKimm-Breschkin J, Mills G, Nguyen V, Owens IJ, Parry N, Shanahan SE, Smith D, Watson KG, Wu WY, Tucker SP.

J Med Chem. 2005 Apr 21;48(8):2964-71.

PMID:
15828835
6.

Zanamivir. A potent and selective inhibitor of influenza A and B viruses.

Aoki FY, Hayden FG.

Clin Pharmacokinet. 1999;36 Suppl 1:v-ix. Review. No abstract available.

PMID:
10429834
7.

[Role of neuraminidase inhibitors for the treatment of influenza A virus infections].

Ferraris O, Escuret V, Bouscambert-Duchamp M, Lina B, Morfin F.

Pathol Biol (Paris). 2010 Apr;58(2):e69-78. doi: 10.1016/j.patbio.2010.01.011. Epub 2010 Mar 19. Review. French.

PMID:
20303677
8.

Neuraminidase inhibitor resistance in influenza viruses.

Reece PA.

J Med Virol. 2007 Oct;79(10):1577-86. Review.

PMID:
17705169
9.

Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses.

Farrukee R, Mosse J, Hurt AC.

Expert Rev Anti Infect Ther. 2013 Nov;11(11):1135-45. doi: 10.1586/14787210.2013.842466. Epub 2013 Oct 7. Review.

PMID:
24093683
10.

Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir.

Masuda T, Shibuya S, Arai M, Yoshida S, Tomozawa T, Ohno A, Yamashita M, Honda T.

Bioorg Med Chem Lett. 2003 Feb 24;13(4):669-73.

PMID:
12639555
11.

CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.

Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S.

Antimicrob Agents Chemother. 2009 Jan;53(1):186-92. doi: 10.1128/AAC.00333-08. Epub 2008 Oct 27.

12.

Attaching zanamivir to a polymer markedly enhances its activity against drug-resistant strains of influenza a virus.

Weight AK, Haldar J, Alvarez de Cienfuegos L, Gubareva LV, Tumpey TM, Chen J, Klibanov AM.

J Pharm Sci. 2011 Mar;100(3):831-5. doi: 10.1002/jps.22338. Epub 2010 Aug 25.

13.

Antiviral drugs for influenza 2012-2013.

[No authors listed]

Med Lett Drugs Ther. 2012 Dec 10;54(1405):97-8. Review. No abstract available.

PMID:
23223245
14.

Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.

Smith PW, Sollis SL, Howes PD, Cherry PC, Starkey ID, Cobley KN, Weston H, Scicinski J, Merritt A, Whittington A, Wyatt P, Taylor N, Green D, Bethell R, Madar S, Fenton RJ, Morley PJ, Pateman T, Beresford A.

J Med Chem. 1998 Mar 12;41(6):787-97.

PMID:
9526555
15.

A surface plasmon resonance assay for measurement of neuraminidase inhibition, sensitivity of wild-type influenza neuraminidase and its H274Y mutant to the antiviral drugs zanamivir and oseltamivir.

Somasundaram B, Fee CJ, Fredericks R, Watson AJ, Fairbanks AJ, Hall RJ.

J Mol Recognit. 2015 Sep;28(9):521-7. doi: 10.1002/jmr.2467. Epub 2015 Mar 2.

PMID:
25727669
16.

Viral M2 ion channel protein: a promising target for anti-influenza drug discovery.

Moorthy NS, Poongavanam V, Pratheepa V.

Mini Rev Med Chem. 2014;14(10):819-30. Review.

PMID:
25342196
17.

Optimizing antiviral therapy for influenza: understanding the evidence.

Ison MG.

Expert Rev Anti Infect Ther. 2015 Apr;13(4):417-25. doi: 10.1586/14787210.2015.1018183. Epub 2015 Feb 19. Review.

PMID:
25695406
18.

[Sensitivity of the epidemic and pandemic influenza virus strains to zanamivir (Relenze) in in vitro experiments].

L'vov DK, Burtseva EI, Galegov GA, Beliakova NV, Shevchenko ES, Kolobukhina LV, Merkulova LN, Prilipov AG, Leneva IA, Baranov NI, Gorelikov VN, Abramov DD.

Vopr Virusol. 2010 Nov-Dec;55(6):10-4. Russian.

PMID:
21381333
19.

Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.

Magano J.

Chem Rev. 2009 Sep;109(9):4398-438. doi: 10.1021/cr800449m. Review. No abstract available.

PMID:
19537777
20.

Correlation analyses on binding affinity of sialic acid analogues and anti-influenza drugs with human neuraminidase using ab initio MO calculations on their complex structures--LERE-QSAR analysis (IV).

Hitaoka S, Matoba H, Harada M, Yoshida T, Tsuji D, Hirokawa T, Itoh K, Chuman H.

J Chem Inf Model. 2011 Oct 24;51(10):2706-16. doi: 10.1021/ci2002395. Epub 2011 Sep 13.

PMID:
21870866

Supplemental Content

Support Center